Key result
The PDE4 inhibitor rolipram does not affect the positive inotropic effects of β₁- or β₂-adrenoceptor stimulation in ventricular trabeculae from explanted human hearts.
Why the study?
Does the PDE4 inhibitor rolipram affect the positive inotropic effects of β-adrenoceptor stimulation in human ventricular trabeculae?
Population
Ventricular trabeculae from explanted human hearts
Design
Editorial
Authors
Loading...
PDE4 inhibition does not alter ventricular inotropic responses to beta-adrenergic stimulation, suggesting a lower ventricular arrhythmogenic risk than previously feared.
Does the PDE4 inhibitor rolipram affect the positive inotropic effects of β-adrenoceptor stimulation in human ventricular trabeculae?
PDE4 inhibition does not alter ventricular inotropic responses to beta-adrenergic stimulation, suggesting a lower ventricular arrhythmogenic risk than previously feared.
Thomas Eschenhagen (2013) reported an editorial. PDE4 inhibitor rolipram was evaluated on Positive inotropic effects of β₁- or β₂-adrenoceptor stimulation. The PDE4 inhibitor rolipram does not affect the positive inotropic effects of β₁- or β₂-adrenoceptor stimulation in ventricular trabeculae from explanted human hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: